Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + toripalimab + anlotinib for second-line advanced or unresectable soft tissue sarcoma
ChiCTR2400090218Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, toripalimab and anlotinib in soft tissue sarcoma (STS), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Sep 2024; status: recruiting.
02
Drugs
tucidinostattoripalimabanlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2400090218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090218.